Celebrating 50 years of scientific
advancement –
learn more
Visit JCR Japan
Visit JCR Japan
Home
Who we are
Innovation
Pipeline
Patients & families
Our commitment
Partnerships
Investors & media
Our products
Contact us
Moises Zanetti
JCR Pharmaceuticals enhances delivery of AAV gene therapy to central nervous system and muscle with novel capsid engineering platform technology
by Moises Zanetti
JCR Pharmaceuticals announces licensing agreement with Menagen to commercialize Agalsidase Beta BS I.V. Infusion [JCR] across nine MENAT markets
by Moises Zanetti
Corporate governance report
by Moises Zanetti
JCR Pharmaceuticals to present at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
by Moises Zanetti
Notice of orphan drug designation for JR-446 for mucopolysaccharidosis type IIIB by Ministry of Health, Labour and Welfare of Japan
by Moises Zanetti
JCR Pharmaceuticals unveils new corporate tagline, “Life is Rare,” to mark its 50th anniversary
by Moises Zanetti
Notice of personnel change
by Moises Zanetti
Notice of organizational and personnel changes
by Moises Zanetti
Notice of personnel change
by Moises Zanetti
PHC and JCR GROWJECTOR L automated injection device wins 2025 Kids Design Award
by Moises Zanetti
1
2
3
…
6
Privacy Preference Center
Privacy Preferences
